Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus FOLFIRI in metastatic colorectal cancer
NCT00457691Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Sunitinib + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Progression-Free Survival at 30 months. Started Jun 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00457691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457691.